Fleebs-Logo
Details werden geladen...

New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer | The Manila Times

More durable, deeper PSA response in patients treated with Pluvicto plus standard of care (ARPI + ADT) vs. SoC aloneDeep PSA reduction higher in patients receiving Pluvicto combination vs. SoC at 12, 24 and 48 weekssNDA filed in US, China and Japan; decisions expected H2 2026Basel, May 17, 2026 - Novartis today announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses with Pluvicto® (lutetium (177Lu) vipivotide tetraxetan) combined with standard of care (SoC) in PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC). Data were presented as a rapid oral presentation at the American Urological Association Annual Meeting 2026.

Ähnliche Seiten

https://www.finanznachrichten.de/nachrichten-2026-05/68517602-novartis-pharma-ag-new-psmaddition-data-show-58-lower-risk-of-psa-progression-with-pluvicto-in-metastatic-hormone-sensitive-prostate-cancer-399.htm

Novartis Pharma AG: New PSMAddition data show 58% lower risk of PSA progression with Pluvicto in metastatic hormone-sensitive prostate cancer

https://www.finanznachrichten.de/nachrichten-2026-05/68517602-novartis-pharma-ag-new-psmaddition-data-show-58-lower-risk-of-psa-progression-with-pluvicto-in-metastatic-hormone-sensitive-prostate-cancer-399.htm
https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/immuneering-reports-173-months-median-overall-survival-in-first-line-metastatic-pancreatic-cancer-patients-treated-with-atebimetinib-plus-chemotherapy/2349698

Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy | The Manila Times

https://www.manilatimes.net/2026/05/22/tmt-newswire/globenewswire/immuneering-reports-173-months-median-overall-survival-in-first-line-metastatic-pancreatic-cancer-patients-treated-with-atebimetinib-plus-chemotherapy/2349698
https://www.manilatimes.net/2026/05/21/tmt-newswire/globenewswire/novartis-advances-rlt-innovation-and-reinforces-leadership-in-prostate-cancer-breast-cancer-and-hematology-with-new-data-at-asco-and-eha/2348825

Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA | The Manila Times

https://www.manilatimes.net/2026/05/21/tmt-newswire/globenewswire/novartis-advances-rlt-innovation-and-reinforces-leadership-in-prostate-cancer-breast-cancer-and-hematology-with-new-data-at-asco-and-eha/2348825
https://www.finanznachrichten.de/nachrichten-2026-05/68555988-novartis-pharma-ag-novartis-advances-rlt-innovation-and-reinforces-leadership-in-prostate-cancer-breast-cancer-and-hematology-with-new-data-at-asco-399.htm

Novartis Pharma AG: Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA

https://www.finanznachrichten.de/nachrichten-2026-05/68555988-novartis-pharma-ag-novartis-advances-rlt-innovation-and-reinforces-leadership-in-prostate-cancer-breast-cancer-and-hematology-with-new-data-at-asco-399.htm
https://www.manilatimes.net/2026/05/20/tmt-newswire/globenewswire/ipsen-announces-late-breaking-data-from-first-head-to-head-study-comparing-dysport-and-botox-in-adults-with-upper-limb-spasticity/2347653

Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity | The Manila Times

https://www.manilatimes.net/2026/05/20/tmt-newswire/globenewswire/ipsen-announces-late-breaking-data-from-first-head-to-head-study-comparing-dysport-and-botox-in-adults-with-upper-limb-spasticity/2347653
https://www.manilatimes.net/2026/05/19/tmt-newswire/globenewswire/roche-to-present-new-data-at-asco-2026-reinforcing-giredestrants-potential-to-transform-the-treatment-paradigm-in-early-breast-cancer/2346752

Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer | The Manila Times

https://www.manilatimes.net/2026/05/19/tmt-newswire/globenewswire/roche-to-present-new-data-at-asco-2026-reinforcing-giredestrants-potential-to-transform-the-treatment-paradigm-in-early-breast-cancer/2346752